The US Food and Drug Administration has confirmed the approval of a new prostate cancer drug developed by Medivation and Astellas Pharma for men who have failed to respond to hormone therapy and chemotherapy. The drug, known as Xtandi, belongs to a new class of drugs known as androgen inhibitors and works by interfering in testosterone's ability to bind prostate cells together. The drug will reportedly cost (Dollar) 7,450 for a 30-day supply with analysts predicting that the ...
via Medindia Health News More READ For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com
Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2012/09/new-prostate-cancer-drug-developed-by.html
No comments:
Post a Comment